Evonik Industries/€EVK

1D1W1MYTD1Y5YMAX

About Evonik Industries

Evonik Industries AG, a German multinational, specializes in producing specialty chemicals, primarily focusing on consumer goods, animal nutrition, and pharmaceuticals. Founded in 1873, the company operates globally and is structured into multiple segments including Specialty Additives, Nutrition & Care, and Smart Materials among others. As a publicly traded entity, it is listed on the Frankfurt Stock Exchange under the ticker EVK.
Ticker
€EVK
Sector
Materials
Primary listing
XETRA
Employees
30,356
Headquarters
Essen, Germany
Website
evonik.com

EVK Metrics

BasicAdvanced
€8.2B
67.20
€0.26
0.54
€1.00
5.73%

What the Analysts think about EVK

Analyst ratings (Buy, Hold, Sell) for Evonik Industries stock.
Analyst projections of the future price of Evonik Industries stock.

Bulls say / Bears say

Evonik’s second-quarter adjusted EBITDA rose 24% to €630 million, while sales increased 11% on 7% higher volumes and prices. Management raised 2026 adjusted EBITDA guidance to €2.0–2.2 billion from €1.7–2.0 billion. (Evonik, Reuters)
Advanced Technologies is showing stronger pricing and utilisation, with second-quarter adjusted EBITDA up 25% to €333 million and its margin reaching 20.2%. Methionine momentum is expected to continue into the third quarter, while high-performance polymers are benefiting from improved demand. (Evonik, MarketScreener)
The extended Tailor Made programme could make Evonik leaner and more competitive, with about 3,200 further roles due to be removed by 2029. Exiting the loss-making polyester business should also reduce exposure to structurally weak activities and support management’s focus on cash and debt ratios. (Evonik, Evonik)
A significant part of the earnings uplift comes from supply bottlenecks affecting Asian competitors after Middle East shipping disruption. Evonik says this benefit should weaken as shipping normalises, and management expects a steep earnings normalisation in the fourth quarter. (Reuters, Evonik)
Underlying demand remains uneven rather than broadly recovered: first-quarter adjusted EBITDA fell 12%, with weaker volumes in several businesses, while analysts have warned that softer demand and rising Chinese export pressure could limit future pricing and margin gains. (Evonik, MarketScreener)
The quality of the profit recovery is still a concern: second-quarter net income fell to €84 million from €120 million despite higher adjusted EBITDA. Ongoing job cuts, business closures and restructuring costs could absorb cash and keep reported earnings well below the adjusted figures. (Evonik, Evonik)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.

EVK Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

EVK Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing EVK

AllEURGBPUSD
Funds
Fund name
Fund size
€EVK weighting
iShares MDAX€EXID
€34M2.85%
iShares MDAX€EXS3
€1.5B2.83%
iShares STOXX Europe 600 Chemicals€EXV7
€104M2.19%
SPDR MSCI World Materials€WMAT
€198M0.17%
iShares MSCI Europe SRI€IESE
€3.1B0.16%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.